Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A new clinical trial at Oxford's Churchill Hospital plans to study the safety of a new experimental drug to treat a form of leukaemia, called Acute Myeloid Leukaemia (AML).

Acute myeloid leukaemia is the most common aggressive blood cancer and there are about 2,200 new cases in the UK each year. It can be hard to treat, especially in patients over 65 years of age, and is often fatal within a year of diagnosis. Therefore, there is an urgent need for more effective therapies.

Read more (Oxford University Hospitals NHS Foundation Trust website)